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Introduction
Patients with traumatic brain injury (TBI) have variable
outcomes subject to intracranial hypertension, ischemia,
hypotension, and various biochemical alterations. Intracranial
pressure (ICP) monitoring is indicated in all severe head injury
cases with detectable lesions by computed tomography (CT)
scan of the head as it has been shown that patients with
ICP > 20 mm Hg have poor outcome if not subjected to
medical/surgical management for intractable intracranial
hypertension. Despite adequate decompression for raised ICP,
a subset of patients remain who continue to deteriorate and
have poor neurologic outcome at long-term follow-up. This
is being attributed to ongoing biochemical changes in
brain tissue (secondary insult/ongoing insults) even after
decompressive craniectomy (DC), and this calls for the need
for monitoring of brain biochemistry for understanding these
changes.Multimodality neurointensivemonitoring is standard
of care for decision making in all severe TBI cases at present in
most neurotrauma units. Neuromonitoring tools, such as
cerebral microdialysis, may contribute to understanding the
pathomechanisms of acute brain injury, provide an early
warning of secondary cerebral deterioration (therapeutic
window of opportunity), and help in selecting the patients
most suitable to benefit from this very invasive surgical rescue
therapy (►Fig. 1). Furthermore, cerebral microdialysis can be
used as a measure of the effect of DC on neurochemistry
derangement and brain energy crisis jeopardizing the injured
brain.
Cerebral microdialysis is a means to monitor cerebral
biochemistry and has been in use globally in human studies
for various conditions since the past two decades. The various
compounds measured by cerebral microdialysis include the
glucose, pyruvate, lactate, glycerol, glutamate, and urea.
Keywords
► cerebral microdialysis
► severe traumatic
brain injury
► decompressive
craniectomy
► ischemia
► mitochondrial
dysfunction
Abstract Patients with traumatic brain injury (TBI) have variable outcomes subject to intracranial
hypertension, ischemia, hypotension, and various biochemical alterations. Multimodality
neurointensive monitoring is standard of care for decision making in all severe TBI cases at
present inmost neurotrauma units. Neuromonitoring tools, such as cerebral microdialysis,
may contribute to understanding the pathomechanisms of acute brain injury, provide an
early warning of secondary cerebral deterioration (therapeutic window of opportunity),
and help in selecting the patients most suitable to benefit from this very invasive surgical
rescue therapy. Cerebral microdialysis can be used as a measure of the effect of
decompressive craniectomy on neurochemistry derangement and brain energy crisis
jeopardizing the injured brain. Present review discusses the cerebral microdialysis, its
usefulness, and role in prognostication of severe TBIs, especially in patients post-
decompressive craniectomy. The authors also discuss the current consensus guidelines on
usage of cerebral microdialysis in TBI patients.
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Studies on TBI patients using microdialysis have shown that
injured parts of the brain contain high lactate levels
corresponding to significant acidosis.
Cerebralmicrodialysis canmonitor brain tissuebiochemical
changes bedside, continuously (1 hourly) by means of a thin
catheter inserted in the brain parenchyma, and dialysate thus
obtained can be analyzed allowing real-time diagnosis of
ongoing ischemia at bedside. Insertion of microdialysis
catheters has been shown to be safe in many studies
available and is being used for neuromonitoring already
globally in advanced neurointensive units where this facility
is available.
Rise in lactate (acidosis) and in lactate/pyruvate ratio (LPR)
has been noted in ischemic brains especially in penumbra
zone in such cases, and these biochemical changes can get
altered further with worsening of ischemia/hypoxia, thereby
suggesting if interventions to reduce ischemia (increase of
cerebral perfusion/cerebral blood flow or decreasing ICP by
medical or surgical means) are implemented well in time,
outcome in such cases could be improved by improving local
cerebral blood flow and decreasing ischemia. There is likely to
be a therapeutic windowof biochemical alterations preceding
rise in ICP/fall in cerebral perfusion pressure (CPP) in these
cases, and there exists probably a time period during which
early timely interventions can be beneficial.
Principle of Microdialysis
Microdialysis is a minimally invasive technique in which a
thin probe, with a semipermeable dialysis membrane at its
tip, is inserted into the brain for continuous sampling of the
brain interstitial fluid.
Themicrodialysis catheter takes up substances delivered by
the blood, for example glucose and drugs, but also substances
released from the cells, for example markers of cellular
metabolism. The interstitial fluid is the “cross road” of all
substances passing between cells and blood capillaries. The
dialysis membrane at the distal end of amicrodialysis catheter
functions like a blood capillary. Molecules at high
concentration in the extracellular fluid equilibrate across the
semipermeable membrane. The enriched perfusate (i.e., the
dialysate) is collected via an outlet tube and can be analyzed.
Chemical substances from the interstitial fluid diffuse
across the membrane into the perfusion fluid inside the
catheter. Monitoring this compartment in the brain allows
the clinician to have critical information about the
biochemistry of neurons and glia and how seriously brain
cells are affected by, for example ischemia, hyperemia,
trauma, vasospasm, as well as various physiologic and
pharmacologic interventions (►Fig. 2a–d).
Depending on the availability of an appropriate analytical
assay, virtually any solublemolecule in the interstitial fluid can
be measured by microdialysis. Most commonly, microdialysis
catheter probes (molecular weight cutoff of 20 kDa, 10-mm
membrane length, and an external diameter of 0.6 mm) are
placed in the perilesional tissue. The catheter can also be
placed via burr hole in patients beingmanaged conservatively/
on contralateral side for normal control sample assays. The
probes are perfused through a precision microdialysis pump
with CNS perfusion fluid at 0.3 to 2 µL/min and samples
collected for bedside analysis.
The “recovery” of a particular substance is defined as the
concentration in the dialysate expressed as a percent of the
concentration in the interstitial fluid. Factor affecting recovery
of an analytes include perfusion flow rate, molecular weight
cutoff of the dialysis membrane, surface area of the dialysis
membrane (length and diameter of the probe), diffusion rate
in dialysis membrane, blood flow rate, metabolism rate, and
extent of tissuevascularization. In particular,measuredvalues
for interstitial products vary with perfusion rates; the lower
the rate (0.3 µL/min), the higher the relative recovery of the
molecule.1 Concentrations of glucose, lactate, pyruvate,
glutamate, and glycerol in the microdialysate are analyzed
using the microdialysis analyzer.
By the use of advanced neuromonitor tools, such as
cerebral microdialysis, in the injured brain, the clinician is
provided with a very early warning of secondary cerebral
deterioration that offers the opportunity to deliver targeted
therapy before irreversible neuronal damage occurs.
Biochemical data are more informative, if integrated with
other neurophysiologic parameters commonly monitored
after an acute brain injury, such as ICP, CPP, mean arterial
pressure (MAP), and plasma glucose.
Microdialysis as a Measure of Brain Energy
Metabolism Alterations, Brain Tissue
Ischemia, Excitotoxicity, and
Neuroinflammation after TBI
TBI is responsible for a complex dysfunction in brain energy
metabolism. Oxygen is needed for oxidative phosphorylation
in the mitochondria.
Under normal aerobic conditions, glucose is converted to
pyruvate by glycolysis and pyruvate is thenmetabolized in the
citric acid cycle and themitochondrial respiratory chain. InTBI,
shear forces and the release of free radicals and intracellular
calcium lead to inactivation of mitochondrial respiration and
Fig. 1 Cerebral microdialysis and neuromonitoring tools offer
therapeutic window of few hours before new-onset clinical
symptoms.
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the stages of the Krebs cycle, leading to mitochondrial
dysfunction and brain energy crisis. In fact, with insufficient
oxygen delivery, neurons must rely on anaerobic metabolism
of glucose for energy. During ischemia, there is a shift from
aerobic to anaerobic metabolism, and pyruvate, unable to
enter the citric acid cycle, is reduced to lactate, accepting
electrons from NADH and so providing the NAD necessary for
glycolysis to continue. The extracellular reflection of these
intracellular events is: reduction in glucose and pyruvate and
increase in lactate and LPR. The use ofmicrodialysis allows the
manifestation of this “energy crisis” (►Fig. 3) to be detected
and monitored over time and the effect of therapeutic
intervention to be evaluated.
Glutamate is another small molecule measured by
microdialysis that may be used as a marker of excitotoxicity,
which is a proposed mechanism of secondary brain injury,
mediated by massive calcium influx into brain cells via
glutamate-mediated opening of neuronal calcium channels.2,3
Glutamate has been seen to be elevated 100- to 200-fold in
severe primary human TBI, and in very severe secondary
insults, it is correlated with herniation, hypoxia/ischemia, and
poor outcome.4–6
Glycerol is a lesswidely reportedbutwell-validatedmarker
of free radical generation, bimolecular leaflet cell membrane
damage, phospholipid breakdown, and consequent free-fatty
acid release. This results from hypoxic/ischemic events, as
well as calcium release into neurons and astrocytes, via the
inactivation of protective enzymes such as peroxidase and
superoxide dismutase, among others.4,7,8
Cerebral microdialysis is a well-established research tool
that has enormously contributed to the authors’understanding
of the derangements occurring in the acutely injured brain, as
demonstrated by a rich literature after acute brain injury in
humans.
In a population of comatose-operated patients with
secondary brain ischemia following aneurysmal subarachnoid
hemorrhage (SAH) and severe TBI, Dizdarevic et al9 conducteda
Fig. 2 (a) Cerebral microdialysis catheter and microvial used for cerebral microdialysis. (b) Microdialysis catheter as universal biosensor/blood capillary.
(c) Cerebral microdialysis analyzer used to monitor the values of dialysate bedside. (d) Schematic picture showing principle of microdialysis with
microdialysis in center collecting products of cellular metabolism from cell and interstitial fluid components from capillary by diffusion.
Fig. 3 Schematic representation of citric acid cycle showing energy
metabolism in brain tissue. ADP, adenosine diphosphate; ATP,
adenosine triphosphate; TCA, tricarboxylic acid.
Indian Journal of Neurosurgery Vol. 6 No. 2/2017
Cerebral Microdialysis Gupta, Mazzeo88
prospective, randomized controlled study comparing relative
effectiveness of the two popular management strategies for
head injury such as ICP-targeted therapy with cerebral
microdialysis monitoring according to the modified Lund’s
concept or CPP-targeted therapy. The authors found that
patients treated with ICP-targeted therapy with microdialysis
monitoring had significantly lower mortality rate as compared
with those treated with CPP-targeted therapy. Patients
monitored with microdialysis who had poor outcome had
lower mean values of glucose and higher mean values of
glycerol and LPR as compared with those who had good
outcome. There was no difference in the mortality outcome
between aneurysmal SAHandsevere TBI in the twogroups. The
authors concluded that the modified Lund’s concept, directed
at bedside real-time monitoring of brain biochemistry by
microdialysis, showed better results compared with CPP-
targeted therapy in this patient population.
Omerhodzić et al10 performed an observational
prospective clinical study on the treatment and outcome of
51 patients with SAH and traumatic intracranial hemorrhage.
Positive correlation was found between brain interstitial
glucose level and outcome at 1-year follow-up (when
glucose level was lower, the patient Glasgow outcome scale
[GOS] score was worse), suggesting that early initiation of
appropriate therapeutic strategies to overcome cerebral
ischemia and secondary brain damage eventually leads to
better patient outcome.
Karathanou et al11 investigated the usefulness of cerebral
microdialysis in predicting the outcomes of 38 TBI patients
and concluded that biochemical parameters analyzed using
microdialysis could serve as predictor indexes of clinical
outcome several months after the injury.
Rostami and Bellander12 investigated the correlation of
glucose levels in peripheral blood, subcutaneous (SC) fat,
and extracellular intracerebral tissue in patients with
severe TBI during neurointensive care. They found a
significant positive correlation between levels of glucose
in peripheral blood, SC fat, and noninjured brain during the
initial 12 hours but not in injured brain. They concluded
that there is a good correlation between blood and adipose
tissue glucose levels during initial and later time points in
the neurointensive care unit whereas the correlation
between blood and brain glucose levels seems to be more
individualized among patients. This emphasizes the
importance of using intracerebral microdialysis to ensure
adequate intracerebral levels of glucose in patients suffering
from severe TBI and to detect hypoglycemia in the brain
despite normal levels of blood glucose.
In a study13 to determine the relationship between the
fundamental biochemical markers and neurologic outcome in
a large cohort of patients with TBI, it was suggested that
extracellular metabolicmarkers asmeasured bymicrodialysis
are independently associated with outcome following TBI.
Furthermore, in a large population of TBI patients, Bullock
and coworkers demonstrated that the results of microdialysis-
based neurochemical monitoring correlate with quantitation of
ischemic events, as measured by a simple five-item scoring
system, taking into account the occurrence of specific
potentially brain-damaging events (hypoxemia, hypotension,
low cerebral blood flow, herniation, and low CPP).14
Recently, in apopulationof TBI patients undergoing spreading
depolarization (SD) monitoring, with electrocorticography, the
association of SD and neurochemical markers as measured by
microdialysis were studied.15 The authors showed that
extracellular glutamate (50 µmol/L) and lactate (3.7 mmol/L)
were significantly elevated on day 0 in patients with SD.
Furthermore, glutamate and LPR progressively increased with
the number of SDs, exceeding the pathologic threshold for
excitotoxicity (glut > 50) and metabolic crisis (LPR > 40). The
same group also demonstrated a strong association between SD
and the occurrence of secondary insults after TBI (low CPP, low
MAP, high temperature).16 These results suggest SD as an
important pathomechanism of secondary brain damage after
TBI and confirm the role of microdialysis in the study of
pathomechanism of brain injury.
The role of neuroinflammation as a key pathomechanism of
damage after acute brain injury has also been investigatedwith
cerebral microdialysis. Posttraumatic neuroinflammation is
characterized by glial activation, leukocyte recruitment, and
upregulation and secretion of mediators such as cytokines and
chemokines. In particular, Helmy et al demonstrated the
different pattern of response in brain and peripheral blood of
cytokines production and the difference in cytokines profile
after recombinant human IL-1ra administration in a phase II
randomized control trial.17,18
The use of microdialysis monitoring to evaluate putative
neuroprotective drugs after severe TBI has been also
documented in clinical trials, demonstrating the utility of
this monitoring tool, not only to measure the effect of a
treatment on brain biochemistry19 but also to detect the brain
interstitial level of intravenous administered neuroprotective
drugs.20 This can help for safer dose optimization to achieve
target concentrations of putative neuroprotectant drugs for
neuroprotection in future TBI studies.
Cerebral Microdialysis Usefulness in
Neuromonitoring after Decompressive
Craniectomy
Neuromonitoring can be a measure of the effect of treatment
(i.e., DC) on cerebral ischemia and hypoxia, as it relates to
neurologic outcomes. The results of neuromonitoring can offer
clinicians a perspective on the appropriate time window for
the investigated rescue treatment21–23 (►Figs. 4, 5). Placement
of catheter is desired inpenumbra zoneperipheral to contused
brain tissue or on the same side in noneloquent area after
evacuation of subdural hematoma (►Fig. 6).
Guidance of critical care management after DC,
especially in those cases characterized by occurrence of a
hyperemic response after the procedure, may be an
important next step. In fact, postoperative derangement in
cerebrovascular pressure reactivity may be present after DC
and could cause malignant cerebral hyperemia, as may be
seen in the operating room in the case of very high CPP.24
Failure of restoration of brain energy metabolism resulting
from a persistent energy metabolic crisis may occur,
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demonstrated by mitochondrial dysfunction or signs of
cerebral ischemia, and it clearly needs further evaluation.24
Overall, the evaluation of the effects of DC on
neurochemistry and brain oxygen delivery may contribute
to a better understanding of the role of this procedure in the
treatment of intracranial hypertension.
Gupta et al25,26 studied a cohort of 41 adult patients with
severe TBI undergoing DC. Twenty-six (63.4%) patients had
a favorable outcome (GOS score 4 or 5) and 15 patients
(36.6%) had an unfavorable outcome (GOS scores 1–3) at
6 months’ follow-up.
All patients were managed in the neurointensive care
unit with multimodality monitoring over a course of 5 days
following DC. Total 3,813 hours of monitoring values of
various microdialysis variables were obtained. There were
no episodes of catheter insertion–induced hematoma or
meningitis.
In these studies, the authors demonstrated significant
cerebral biochemical alterations, as detected by cerebral
microdialysis.
Glucose
Therewasno significantdifference inmean randomblood sugar
(RBS) (7.26 vs. 7.61 mmol/L; p ¼ 0.166) and mean cerebral
glucose (1.84 vs. 1.95 mmol/L; p ¼ 0.221) values among the
good or bad outcome groups, respectively. A poor correlation
between plasma and cerebral glucose for the entire cohort was
noted (p ¼ 0.642). This suggests that brain interstitial
microdialysate glucose values are not always reflective of
changes in systemic glucose. A significant difference was
noted in the incidence of hyperglycemia (RBS > 10 mmol/L)
andhypoglycemia (RBS < 5mmol/L) between the twooutcome
groups (p < 0.0001). The microdialysis glucose values during
the episodes of hyperglycemia or hypoglycemia did not show a
significant difference between the two groups. However, the
authors noticed that microdialysis glucose values showed a
rising trend over the course of 5 days of monitoring in the good
outcome group. Similarly, the good outcome group showed
rising microdialysis glucose to blood glucose ratios. This
indicates a recovering metabolic state in the brain tissue that
may indicate a good outcome25,26 (►Fig. 7).
Fig. 5 Collection of dialysate bedside for neurobiochemistry of
microdialysis sample.
Fig. 6 Noncontrast CT showing focal hemorrhagic left frontal contusion (panel a). After removal of contusion, placement of microdialysis
catheters in penumbra zone and normal contralateral (panel b).
Fig. 4 Microdialysis catheter being inserted after decompressive
craniectomy.
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Difference between the two groups, comparing episodes of
cerebral hypoglycemia during systemic hypoglycemic
episodes (RBS < 5 mmol/L), was significant (p ¼ 0.0026).
This probably reflects increased susceptibility of brain tissue
to hypoglycemia, related to impaired autoregulation, in the
poorer outcome group. The previous assumption that cerebral
extracellular glucose concentration would change in parallel
with blood glucose values may be an oversimplification.27 An
increased metabolism of intracerebral glucose may lead to
lower microdialysis glucose values following head injury.28
Similarly, poor correlation has been also reported between
blood and extracellular brain glucose in patient with SAH.29
Abate and colleagues attributed poor control of microdialysis
glucose based on blood glucose values secondary to the
metabolic heterogeneity that may be expected in TBI
patients.30
Nagel et al noted weak correlation between cerebral and
serum glucose; however, the trend of values for cerebral
hypoglycemia, LPR, and CPP correlated well with outcomes
in their series.31
Lactate/Pyruvate Ratio
After DC, Gupta et al showed that mean LPR was
significantly higher in the poor outcome group than the
good outcome group (mean 80.2 [SD 320.3] vs. 45.8 [SD
169.8]; p < 0.01). CPP had an inverse correlation to the LPR
for the whole cohort as would be expected with increased
perfusion (p ¼ 0.03). An inverse correlation was also seen in
the unfavorable outcome group (p < 0.01).25,26
Nikaina et al previously showed that CPP and LPR have
significant effects on the long-term outcome prognosis after a
spontaneous cerebral hematoma.32 They proposed a cutoff
CPP of  75 mm Hg and LPR  36. Parafarou et al suggested a
CPP cutoff > 75 mmHg, LPR < 37, and glycerol < 72 µmoles/L
as markers of good outcome.23 This study shows somewhat
similar results (LPR < 45 and CPP  70 mm Hg).
In the event of TBI, ischemia and decreased cerebral
blood flow can occur even with CPP  65 to 75 mm Hg.23,33
Therefore, CPP alone is not a reliable indicator to assess
adequacy of the cerebral blood flow in such patients. There
is, however, no consensus for the ideal CPP values in severe
TBI. Some authors have warned about a higher risk of acute
respiratory distress syndrome with a CPP > 70 mm Hg,
with no additional benefit to outcome. A lower CPP goal of
60 mm Hg has been endorsed by the American Association
of Neurological Surgeons, and recently the Brain Trauma
Foundation suggested a general threshold in the area of 50
to 70 mm Hg.34 An elevated LPR can have various causes
such as ischemia, hyperglycolysis, and mitochondrial
dysfunction.35–37 The key to finding the appropriate cutoff
for CPP may depend on keeping a favorable metabolic
profile, as indicated by low LPRs.
Glutamate
Increased levels of extracellular glutamate have been reported
in human TBI, with persistent glutamate elevation seen in the
postinjury period. In ischemic models, levels have been seen
to rise from 2 to > 20 µmol/L.
In the studies by Gupta et al, levels of glutamate were
significantly higher in the bad outcome group than the good
outcome group: 40.31 µmol/L (SD 67.24) versus 21.68 µmol/L
(SD 38.31), p < 0.01.24–26 Recovering trends of glutamate
values were seen in the good outcome group over a
period of 5 days, consistent with previous studies.38 This
confirms that glutamate could be a useful prognostic
marker in TBI.
Mitochondrial Dysfunction and Ischemia
Asmentioned earlier, the LPR elevation has been seen to occur
in conditions of ischemia (with a fall in pyruvate) and also in
mitochondrial dysfunction (with a near normal pyruvate
level). Gupta et al noted that the unfavorable outcome group
showed significantly higher episodes of both mitochondrial
dysfunction and ischemia than the favorable GOS group:
65.9% versus 55.9% (p < 0.0001); 13.9% versus 7.24%
(p < 0.001), respectively.25,26 These changes were more
pronounced with pericontusional catheter placement. The
authors compared the results for the time spent in each
category, post-resuscitation GCS and age to the GOS score at
last follow-up. For most patients being monitored for a period
of 3 to 5 days, this meant that even a 10% increase in ischemia
(8–10hours), as shownbymicrodialysis, doubled their odds of
progressing to a worse outcome group. Similarly, for
mitochondrial dysfunction, the odds ratio was 1.475 (95%
confidence interval [CI]: 1.066–2.040) (p ¼ 0.019). During
episodes of ischemia, the ICP was significantly higher and the
CPP significantly lower.36 In view of the odds of worsening
outcome with each episode of ischemia, close control of CPP
should be maintained.
Ischemia and mitochondrial dysfunction require
different therapies. If a condition is characterized as
Fig. 7 Over 5 days of intracerebral microdialysis (MD) monitoring,
the good Glasgow outcome scale (GOS) showed a rising cerebral MD
glucose and cerebral/blood glucose ratios. MD glucose is expressed
in mmol/L and random blood glucose (RBG) in mmol/L. RBS, random
blood sugar.
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ischemic based on microdialysis values of the LPR and
pyruvate levels, therapy is indicated to increase CPP or to
pharmacologically improve microcirculation. On the other
hand, bedside detection of nonischemic mitochondrial
dysfunction should lead to consideration of novel therapies
targeting mitochondrial function, such as hyperbaric
oxygen36 (►Fig. 8).
It is important to notice that in TBI shifting of energy
metabolism from aerobic to anaerobic glycolysis may occur
not only because of lack of oxygen delivery but also because
of failure of effective utilization of the delivered oxygen due
to mitochondrial dysfunction. This leads to a nonischemic
LPR elevation, which has been designated type 2 elevation.
This is what Vespa and colleagues have demonstrated in
Fig. 8 Low pyruvate levels in ischemia and high pyruvate levels in mitochondrial dysfunction patients as detected by cerebral microdialysis. Lactate/
pyruvate (LP) ratio is raised in both groups. Gluc, cerebral glucose, La, cerebral lactate levels; LPR, lactate/pyruvate ratio PbtO2, brain tissue oxygenation;
Pyr, cerebral pyruvate levels.
Table 1 Summary of the consensus statements and recommendations regarding cerebral microdialysis
Consensus statement 2015 Recommendation Evidence
Methodology of
microdialysis
20-kDa catheters for small molecules
and 100-kDA for large molecules
Flow rate of 0.3 µL/min
with hourly sampling
recommended
Reference values Glucose
(Tier 1 intervention)
< 0.2 mmol/L
< 0.8 mmol/L
Low glucose associated with
poor outcome
L/P ratio
(Tier 1 intervention)
> 40
> 25
High L/P ratio associated with
poor outcome
Lactate > 4 mmol/L L/P ratio better than lactate
Glutamate
(Tier 2)
Raised in ischemia May be useful in prognostication
Glycerol
(Tier 3)
Limited specificity No definitive evidence
Management
guidelines
Glucose Raise RBS if low
Treat perfusion, if low CPP
L/P ratio If ischemia, raise CPP
If low PbtO2,
improve oxygenation
Catheter
placement
Focal injury a) Ipsilateral
b) In normal brain
Multiple catheters may be used
Diffuse injury Right frontal lobe
Monitoring Trend is more important than absolute point values
Abbreviations: CPP, cerebral perfusion pressure; L/P ratio, lactate/pyruvate ratio; PbtO2, brain tissue oxygenation; RBS, random blood sugar.
Indian Journal of Neurosurgery Vol. 6 No. 2/2017
Cerebral Microdialysis Gupta, Mazzeo92
their combined MD and positron emission tomography
(PET) study, in which MD data revealed a 25% incidence of
LPR > 40 but only a 2.4% incidence rate of ischemia, as
indicated by LPR > 40 and glucose < 200 µmol/L or PET-
oxygen extraction fraction > 0.75.37 In addition, LPR
elevations correlated with reduced cerebral metabolic rate
for oxygen, which is a measure of mitochondrial oxidative
metabolism, suggesting that LPR is an indicator of
mitochondrial dysfunction. This observation suggests the
importance of using other markers of cell damage (glycerol
and/or glutamate) in addition to LPR for a correct
interpretation of this variable.
Consensus Guidelines on Use of Cerebral
Microdialysis
A recently held consensus meeting by the international
microdialysis forum, led by P. J. Hutchinson, combined
literature review with expert opinion to produce practical
guidance for the use of cerebral microdialysis (►Table 1).38
Conclusion
Among the several neuromonitoring tools available
nowadays, cerebral microdialysis seems to accomplish
most of the queries that researchers and clinicians ask to
these devices in the care of patients with acute brain injury:
to detect secondary insults in real time, at the time in which
they can still be corrected; to clarify pathomechanisms of
injury; to understand alterations in cerebral energy
metabolism; to evaluate the effect of medical or surgical
interventions on brain metabolism; to evaluate the effect of
invasive rescue therapies such as DC in patients with
intractable intracranial hypertension; to provide markers
of effectiveness of therapeutic intervention; and to help in
designing of clinical studies.
Therefore, monitoring neurochemistry by microdialysis
can possibly provide clinicians with additional information in
several related aspects of management. Robust neurochemical
changes have been detected in response to clinical
pathophysiologic events after an acute brain injury, so that
the specific effect of DC on the different pathomechanisms of
injury can be difficult to isolate from primary injury and
other therapies using these neuromonitoring tools. Although
cerebral microdialysis and other types of multimodality
monitoring have been in use for almost two decades, their
potential is huge for the future. Limits of this monitoring tool
are represented especially by its high cost, its local aspect, and
by the need to experienced personnel, so that its use is not
widely diffused across the globe. Therefore, even if no doubt
exists on its usefulness as research tool, as demonstrated by
two decades of literature in human TBI, the real impact of this
monitoring in dictating specific changes in management
during daily clinical practice remains to be demonstrated in
larger studies.
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